Home multiple
 

Keywords :   


Tag: multiple

Keysight Technologies' PXI VNA Wins Multiple Industry Awards Selected as One of the Most Significant Products of 2014

2015-01-19 11:30:51| Industrial Newsroom - All News for Today

SANTA ROSA, Calif. Keysight Technologies, Inc. (NYSE: KEYS) today announced that it has received three awards for its recently introduced M937XA PXI Vector Network Analyzer. The awards include 1) Product of the Year from Electronic Products magazine, 2) Top Products of the Year 2014 from Microwave and RF magazine...

Tags: of products industry selected

 

PTC's ThingWorx And Axeda Internet Of Things (IoT) Enabling Technologies Win Multiple Excellence Awards At CES 2015

2015-01-19 03:47:47| electronicsweb Home Page

PTC recently announced that the Internet of Things (IoT) enabling technology businesses it acquired in 2014 – ThingWorx and Axeda –received several prestigious awards from Compass Intelligence at last week’s International CES, the world’s largest consumer electronics show

Tags: internet things multiple win

 
 

Trade News: Keysight Technologies' Pxi Vna Wins Multiple Industry Awards

2015-01-14 20:55:54| Auto Parts - Topix.net

Keysight Technologies, Inc. today announced that it has received three awards for its recently introduced M937XA PXI Vector Network Analyzer . The awards include 1) Product of the Year from Electronic Products magazine, 2) Top Products of the Year 2014 from Microwave and RF magazine, and 3) Hot 100 Products of 2014: Test & Measurement from EDN.

Tags: news industry multiple trade

 

Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

2015-01-13 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA (pembrolizumab) with Alimta (pemetrexed), Cyramza (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LLY Exchange: NYSE read more

Tags: enter research agreement types

 

Visteon to Unveil Advanced Connectivity Solutions in Multiple Vehicles at 2015 International CES

2015-01-07 11:30:54| Industrial Newsroom - All News for Today

Global Automotive Supplier Creates Value in Vehicles for Automakers, Dealers and Consumers LAS VEGAS - Visteon Corporation (NYSE: VC) will showcase advanced technology in three different passenger cars to demonstrate how it can increase a vehicle's value throughout its lifecycle by reducing warranty costs and...

Tags: international advanced multiple solutions

 

Sites : [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] next »